Moberg Pharma (MOB) Stock Overview
A pharmaceutical company, develops and commercializes medical products primarily in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MOB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Moberg Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 9.48 |
| 52 Week High | SEK 12.10 |
| 52 Week Low | SEK 6.52 |
| Beta | 1.15 |
| 1 Month Change | -1.46% |
| 3 Month Change | -1.66% |
| 1 Year Change | 16.03% |
| 3 Year Change | -65.15% |
| 5 Year Change | -85.44% |
| Change since IPO | -96.70% |
Recent News & Updates
Recent updates
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
Nov 07
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
May 16
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Feb 12We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Sep 14Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 08Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Nov 16Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
Jan 17Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
Dec 03
Shareholder Returns
| MOB | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.05% | 1.0% | 1.6% |
| 1Y | 16.0% | 0.7% | 5.8% |
Return vs Industry: MOB exceeded the Swedish Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: MOB exceeded the Swedish Market which returned 5.8% over the past year.
Price Volatility
| MOB volatility | |
|---|---|
| MOB Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: MOB has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MOB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 6 | n/a | www.mobergpharma.se |
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) Fundamentals Summary
| MOB fundamental statistics | |
|---|---|
| Market cap | SEK 440.63m |
| Earnings (TTM) | -SEK 257.79m |
| Revenue (TTM) | SEK 12.50m |
Is MOB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOB income statement (TTM) | |
|---|---|
| Revenue | SEK 12.50m |
| Cost of Revenue | SEK 5.96m |
| Gross Profit | SEK 6.54m |
| Other Expenses | SEK 264.33m |
| Earnings | -SEK 257.79m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 17, 2026
| Earnings per share (EPS) | -5.48 |
| Gross Margin | 52.35% |
| Net Profit Margin | -2,062.80% |
| Debt/Equity Ratio | 0% |
How did MOB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 18:46 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moberg Pharma AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |